Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA COVID-2019 vaccine - eTheRNA Immunotherapies

Drug Profile

mRNA COVID-2019 vaccine - eTheRNA Immunotherapies

Latest Information Update: 06 Apr 2020

At a glance

  • Originator eTheRNA Immunotherapies
  • Class RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 24 Mar 2020 Preclinical trials in COVID-2019 infections (Prevention) in Belgium (Intranasal)
  • 24 Mar 2020 eTheRNA Immunotherapies plans clinical trial for COVID-2019 infections in early 2021

Development Overview

Introduction

mRNA vaccine for COVID-2019 infections is being developed by eTheRNA Immunotherapies (spin-off from the VUB university). The development programme is focused on a vaccine candidate that integrates three different technologies, the company's proprietary trimix technology that stimulates dendritic cells into activating a strong CD4 and CD8 T cell response, a combination of T cell epitopes from the virus brought together on a single mRNA construct. An intranasal vaccine delivery platform using a nasal atomizer and a proprietary formulation that delivers the mRNA to the nasal mucosa and optimizes expression will be used. Intranasal delivery has been chosen since the mucosa of the upper respiratory tract are the immune system's primary line of defence. A strong nasal T cell effector and memory response is claimed to fight viral replication, colonization of the lung and thus disease. Preclinical development is underway in Belgium.

A consortium has been formed with North American and European partners to develop the novel mRNA vaccine against COVID-2019 infections. The eTheRNA consortium's approach selects conserved epitopes from the whole viral genome. Creating a vaccine that mounts a strong cellular (T cell) based response against these epitopes offers a better chance to overcome viral variability.

Key Development Milestones

In March 2020, eTheRNA Immunotherapies initiated preclinical development of mRNA COVID-2019 vaccine in Belgium [1] .

Drug Properties & Chemical Synopsis

  • Route of administration Intranasal
  • Formulation unspecified
  • Class RNA vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E (Viral Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Preclinical Belgium Intranasal / unspecified eTheRNA Immunotherapies 24 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
eTheRNA Immunotherapies Originator Belgium
eTheRNA Immunotherapies Owner Belgium

Future Events

Expected Date Event Type Description Updated
01 Jan 2021 Trial Update eTheRNA Immunotherapies plans clinical trial for COVID-2019 infections in early 2021 [1] 27 Mar 2020

Development History

Event Date Update Type Comment
24 Mar 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections (Prevention) in Belgium (Intranasal) [1] Updated 06 Apr 2020
24 Mar 2020 Trial Update eTheRNA Immunotherapies plans clinical trial for COVID-2019 infections in early 2021 [1] Updated 06 Apr 2020

References

  1. eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populations.

    Media Release
Back to top